Cytokinetics, Incorporated (NASDAQ:CYTK) Ratings Summary as of Jun 29, 2018

June 29, 2018 - By Ashley Edward

Cytokinetics, Incorporated (NASDAQ:CYTK) Corporate Logo
Big Money Sentiment decreased to 0.88 in Q1 2018. It has change of 0.23, from 2017Q4’s 1.11. The ratio is negative due to Cytokinetics, Incorporated positioning: 19 sold and 37 reduced. 19 funds acquired stakes and 30 increased stakes. Investors holded 38.16 million in 2017Q4 but now own 36.39 million shares or 4.65% less.
Mason Street Advisors Lc holds 0% or 14,051 shs in its capital. The Connecticut-based Aqr Cap Ltd Liability Co has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Birchview Lp stated it has 0.05% in Cytokinetics, Incorporated (NASDAQ:CYTK). Barclays Public Llc accumulated 23,611 shs. California State Teachers Retirement Systems invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Manufacturers Life Insurance Co The holds 32,907 shs or 0% of its capital. Savings Bank Of Montreal Can accumulated 937 shs. Bancorp Of America De stated it has 43,050 shs. Tekla Capital Management Ltd Company holds 0.04% of its capital in Cytokinetics, Incorporated (NASDAQ:CYTK) for 137,797 shs. Legal And General Group Inc Public Limited reported 93,305 shs. Great West Life Assurance Can holds 0% or 66,603 shs. Art Advsrs Ltd Limited Liability Company accumulated 48,678 shs. Wellington Management Gp Llp reported 2.02M shs. Fmr Limited Liability Co owns 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK) for 2.29 million shs. Essex Invest Ltd Co owns 0.08% invested in Cytokinetics, Incorporated (NASDAQ:CYTK) for 84,690 shs.

Cytokinetics, Incorporated registered $147,942 net activity with 0 buys and 5 insider sales since January 16, 2018. On Thursday, April 5 Blum Robert I also sold $30,090 worth of Cytokinetics, Incorporated (NASDAQ:CYTK). The insider Malik Fady Ibraham sold 3,000 shs worth $26,850.

Cytokinetics, Incorporated (NASDAQ:CYTK) Ratings Coverage

Total analysts of 2 have positions in Cytokinetics Inc (NASDAQ:CYTK) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 19, 2018 according to StockzIntelligence Inc Cytokinetics Inc has 4 analyst reports. On Friday, April 27 the rating was maintained by H.C. Wainwright with “Buy”. On Monday, June 18 the firm has “Buy” rating given by H.C. Wainwright. On Wednesday, February 21 Morgan Stanley maintained Cytokinetics, Incorporated (NASDAQ:CYTK) with “Overweight” rating. On Friday, January 19 the company was maintained by H.C. Wainwright. Listed here are Cytokinetics, Incorporated (NASDAQ:CYTK) PTs and latest ratings.

18/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $24.0000 Maintain
27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $20.0000 Maintain
21/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $17 New Target: $18 Maintain
19/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $20.0 Maintain

The stock increased 1.22% or $0.1 during the last trading session, touching $8.3.Currently Cytokinetics, Incorporated is downtrending after 37.37% change in last June 29, 2017. CYTK has 89,205 shares volume. CYTK underperformed the S&P 500 by 49.94%.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.The firm is worth $449.84 million. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.Currently it has negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.

For more Cytokinetics, Incorporated (NASDAQ:CYTK) news released briefly go to: Streetinsider.com, Nasdaq.com, Nasdaq.com, Benzinga.com or Benzinga.com. The titles are as follows: “Cytokinetics (CYTK) Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular …” released on June 08, 2018, “Mid-Afternoon Market Update: Crude Oil Up Over 1%; Gevo Shares Spike Higher” on June 18, 2018, “Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to …” with a publish date: June 08, 2018, “Mid-Morning Market Update: Markets Open Lower; Vintage Capital To Acquire Rent-A-Center For $15/Share” and the last “42 Stocks Moving In Monday’s Mid-Day Session” with publication date: June 18, 2018.

Cytokinetics, Incorporated (NASDAQ:CYTK) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: